Actinogen Medical

About Actinogen Medical

Actinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking research in Alzheimer’s disease and other chronic neurodegenerative diseases. Actinogen Medical’s lead research candidate, Xanamem™, is a novel drug under development for the treatment of Alzheimer’s disease. Research recently demonstrated that increased cortisol, also known as the “stress hormone”, is associated with cognitive impairment, the development of beta-amyloid plaques and nerve death in the brain – the hallmarks of Alzheimer’s disease. Xanamem™, has been specifically designed to block the production of cortisol in the brain. Actinogen has successfully completed all the necessary early phase studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile, and that it crosses the blood-brain-barrier in concentrations to adequately inhibit the excess production of cortisol in the hippocampus and frontal cortex of the brain, its primary site of action. Actinogen is well advanced in its plans for the Phase II “XanADu” efficacy and safety study with mild Alzheimer’s disease patients in the second half of 2016. This study will be run in Australia, the United Kingdom, and the United States with appropriate regulatory approvals.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Bill Ketelbey

CLINICAL TRIAL:
Please click here for clinical trial information.